EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. - Wikidata - wikimedia - TriplyDB

EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.

EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.

http://www.wikidata.org/entity/Q37174372

about

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 Unleashing the untold and misunderstood observations on vitamin E.Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis Treatment of pediatric brain tumors.Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis.Activated epidermal growth factor receptor in ovarian cancer.Protein kinase inhibitors: contributions from structure to clinical compounds.Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.Postoperative oligo-recurrence of non-small-cell lung cancer: clinical features and survival†.Ultraviolet irradiation can induce evasion of colon cancer cells from stimulation of epidermal growth factor.Socioeconomic inequalities in cancer survival: a population-based study of adult patients diagnosed in Osaka, Japan, during the period 1993-2004.

P2860

Q27654155-4469B326-6D1E-468C-BB75-B42EB2F92D61 Q34049250-68E74CAF-278E-4797-B023-ACBAC7F83F39 Q34581614-91F8260F-E4F0-402D-B012-2E55DA7CB06F Q34754045-8DEFBC1A-8FE0-49D0-A890-C7D7FB98F827 Q35829712-0424F3CD-78EC-417E-8045-6637EBBF4722 Q35946822-9A8843E1-9E68-4B6A-9F2C-037FE4B13DEB Q36649908-7E50D591-3BEF-4A18-AECB-7BF8F098749F Q36953476-C614F8C2-5CA8-4BCA-8CCE-D6BC0EA964BE Q36980961-86300BBC-4067-43D9-ADF1-B4D8F36EA626 Q36981918-9D6A8B9D-300E-46CB-A449-13C4D636F87C Q37417742-2774831D-B898-465F-A8A8-8A5B21B6AFFC Q39407582-68C781B7-41A2-45EB-984D-BD46FC85E8A2 Q41557929-74123E0B-D00F-4114-83AA-328F6F24C905 Q42115280-32F9A772-B4AA-4463-A143-638D32F4F5A0 Q43570367-8EF8A88C-37BF-43A3-B6D1-0A15677052FC

P2860

EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.

http://www.wikidata.org/entity/Q37174372

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

EGFR-targeting drugs in combin ...... bedside, a contrasted reality.

@en

EGFR-targeting drugs in combin ...... bedside, a contrasted reality.

@nl

type

label

EGFR-targeting drugs in combin ...... bedside, a contrasted reality.

@en

EGFR-targeting drugs in combin ...... bedside, a contrasted reality.

@nl

prefLabel

EGFR-targeting drugs in combin ...... bedside, a contrasted reality.

@en

EGFR-targeting drugs in combin ...... bedside, a contrasted reality.

@nl

P1433

Q37174372-A2AD9B4A-FAD8-47CB-900F-D6262A702E46

P1476

Q37174372-4F2FDFDB-8F9D-410F-9C80-C1C892B0714D

P2093

Q37174372-0A4DDCD0-D326-49EF-AB92-53E8D71F81E0

Q37174372-A0489A9F-A34E-47F8-8C61-4B6A4D486E37

Q37174372-F07450DD-4FD2-4F7D-A810-5BB60020C51C

P2860

Q37174372-0163E0E4-64E2-443F-B908-85335A04C52F

Q37174372-0AF59B9C-AE58-41FB-B747-17C7B174848A

Q37174372-18249C0D-69D4-4854-B86C-A7931C95F737

Q37174372-2B5276E5-9DC4-472C-83ED-9A9AC37F6737

Q37174372-30EEF850-3E78-4395-A2A7-B0B7C58FBF3D

Q37174372-3957F7BE-7E75-4B6E-816F-17A184688852

Q37174372-3A7A60B4-EDA5-42AA-86EE-964FF61804EE

Q37174372-43AC69DA-8C7C-4090-AA7A-6581758F4CA3

Q37174372-489B6D1F-9E6F-447B-A463-3CCE3FEA5F55

Q37174372-49B5E905-5413-4324-8AF9-A3016BD29200

P2888

Q37174372-2EF7CD08-D262-4DF8-ADB6-EB3823D92B47

P304

Q37174372-0443CF5F-D7A2-4567-A8BD-1DD90680F289

P31

Q37174372-05E87E18-0961-4082-BF2A-C6CE80845DA3

Q37174372-C1ACB875-7620-41B1-87B7-64124E0EDFF4

P356

Q37174372-CA761E60-5F43-45B6-A3F0-A555215FE581

P407

Q37174372-153A394C-ED04-45B7-8342-0227C2D92A05

P433

Q37174372-F7742D99-AA2D-43F7-9E5F-D97ED887ECD6

P478

Q37174372-2EDA5919-D6CB-49E5-A65D-AACFC2CC4EFD

P577

Q37174372-0D348BE5-08DF-42C8-B1B0-7ECF1D830BEF

Q37174372-CAE56DC2-509C-4045-AD3C-13936F58992F

P5875

Q37174372-0239338D-32DD-46FC-ACF0-89603AAD5F59

P698

Q37174372-47DF5195-B1CF-48C6-A3EE-B7A2DC512412

P921

Q37174372-3D76F136-0544-4F51-A939-00D39D72181A

Q37174372-B4536AB9-0BB9-41D2-9A99-2F96DEEDCFE4

Q37174372-DDEB52A2-615D-486F-94A8-47204C91D568

Q37174372-DF52F362-D603-4A37-B6FE-D29956259489

Q37174372-E486EC97-6D5C-4C90-9A56-AE6ED306AF5E

Q37174372-E947959A-7F55-4F52-AF08-060B59142BEB

P932

Q37174372-F6020E0D-F2F3-4EE9-8E46-A2ADE9265CDF

P356

P1433

British Journal of Cancer

P1476

EGFR-targeting drugs in combin ...... bedside, a contrasted reality.

@en

P2093

B Leyland-Jones

http://www.w3.org/2001/XMLSchema#string

G Milano

http://www.w3.org/2001/XMLSchema#string

J-P Spano

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

The EGFR as a target for anticancer therapy--focus on cetuximab.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.

Why the epidermal growth factor receptor? The rationale for cancer therapy.

P2888

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604373

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2008-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5345062

http://www.w3.org/2001/XMLSchema#string

P698

18506149

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

mechanism of action

membrane proteins

P932

2453033

http://www.w3.org/2001/XMLSchema#string